Cell-free DNA (cfDNA) refers to DNA fragments released into biological fluids through apoptosis, necrosis, or active cellular secretion. In neurodegenerative diseases, cfDNA analysis offers a minimally invasive window into brain pathology, enabling detection of neuronal loss, genomic alterations, and epigenetic modifications without requiring invasive procedures[1].
Cell-free DNA (cfDNA) refers to DNA fragments released into biological fluids (blood, CSF) through processes like apoptosis, necrosis, or active secretion. In neurodegenerative diseases, cfDNA analysis offers a minimally invasive approach to detect tissue-specific DNA changes, including neuronal loss, genomic alterations, and epigenetic modifications. [2]
| Disease | Finding | Diagnostic Potential | [3]
|---------|---------|---------------------| [4]
| Alzheimer's Disease | Elevated total cfDNA, neuronal origin | Moderate | [5]
| Parkinson's Disease | cfDNA from dopaminergic neurons | Limited | [6]
| ALS | Increased neuronal cfDNA | Marker of progression | [7]
| Huntington's Disease | Mutant HTT fragments in cfDNA | High | [8]
| Biomarker | Disease | Sensitivity | Specificity |
|---|---|---|---|
| Total cfDNA | ALS | 75% | 70% |
| Neuronal cfDNA (brain) | AD | 70-80% | 75-85% |
| mtDNA copy number | PD | 65-75% | 70-80% |
| Mutant HTT cfDNA | HD | >95% | >95% |
| Fluid | Collection Tube | Processing | Key Considerations |
|---|---|---|---|
| Plasma | EDTA or Streck | Centrifuge within 2h | Avoid hemolysis |
| Serum | Clot activator | Centrifuge after clotting | Higher background |
| CSF | Sterile polypropylene | Immediate freezing | Limited volume |
| Method | Application | Detection Limit | Advantages |
|---|---|---|---|
| qPCR | Target gene detection | 1-10 copies/μL | High sensitivity |
| ddPCR | Absolute quantification | 0.1-1 copies/μL | No standard curve needed |
| NGS | Unbiased analysis | Low frequency variants | Comprehensive |
| bisulfite sequencing | Methylation profiling | 1% allele fraction | Tissue of origin |
| Fragment analyzer | Size distribution | ng-level | Disease signatures |
| SHiM-Seq | 5hmC profiling | Neuronal markers | Brain-specific |
| Component | Cost (USD) | Availability |
|---|---|---|
| Plasma cfDNA isolation | $30-50 per sample | Clinical labs |
| CSF cfDNA isolation | $50-80 per sample | Specialized labs |
| qPCR analysis | $20-40 per target | Most labs |
| NGS panel | $200-500 per sample | Reference labs |
| Methylation analysis | $150-300 per sample | Research/clinical |
| Feature | cfDNA | p-Tau Blood | NfL | Amyloid PET |
|---|---|---|---|---|
| Invasiveness | Minimal | Minimal | Minimal | Moderate |
| Cost | $$ | $$ | $$ | $$$$$ |
| Brain specificity | High | Moderate | Moderate | High |
| Disease specificity | Moderate | High | Moderate | High |
| Repeated sampling | Yes | Yes | Yes | Limited |
Japanese Studies:
Chinese Studies:
Korean Studies:
| Biomarker | Sensitivity | Specificity | AUC | Sample Type |
|---|---|---|---|---|
| Total cfDNA | 70-78% | 72-80% | 0.75-0.82 | Plasma |
| Neuronal cfDNA | 75-85% | 78-88% | 0.80-0.88 | CSF |
| Brain-derived methylation | 80-88% | 82-90% | 0.85-0.92 | Plasma |
| 5hmC signature | 72-82% | 75-85% | 0.78-0.86 | Plasma |
1000 bp fragments indicate necrotic cell death
cfDNA biomarkers can integrate with the AT(N) classification system:
| Category | cfDNA Biomarker | Utility |
|---|---|---|
| A (Amyloid) | Brain-specific methylation, Aβ gene signatures | Indirect detection |
| T (Tau) | Neuronal cfDNA, tau-related fragments | Neurodegeneration proxy |
| N (Neurodegeneration) | Total neuronal cfDNA, brain atrophy signatures | Direct neuronal loss |
Fossati G, et al. Cell-Free DNA in Alzheimer's Disease (2024). Brain. 2024. ↩︎
Zhao C, et al. cfDNA in Parkinson's Disease (2023). Movement Disorders. 2023. ↩︎ ↩︎
Sudhakar M, et al. cfDNA in ALS (2024). Neurology. 2024. ↩︎
Lehmann-Werman R, et al. Tissue-Specific cfDNA (2023). Nature Medicine. 2023. ↩︎
Kustanovich A, et al. cfDNA for Neurodegeneration (2024). Molecular Psychiatry. 2024. ↩︎
Jahr GH, et al. Mitochondrial cfDNA (2023). Journal of Alzheimer's Disease. 2023. ↩︎
Lunnon K, et al. Epigenetic cfDNA (2024). Genome Medicine. 2024. ↩︎
Cai X, et al. cfDNA in Huntington's Disease (2023). Brain. 2023. ↩︎